Chairman of Meuhedet, Israel’s third-largest health fundTORONTO and HAIFA, Israel, Jan. 30, 2026 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) today announced changes to its board of directors (the “Board”). Effective today, Mr. Eyal Gabbai has been appointed to the Board replacing Dr. Gadi Riesenfeld, who has resigned from the Board. Dr. Riesenfeld will continue to support NurExone as a member of the Company’s Scientific Advisory Board. The C ...

Live Chat on The Biotech Forum sees frequent discussion of specific covered call trades. To see what covered call trades I am currently executing along with a model portfolio of attractive biotech stocks, just initiate your free trial into The Biotech Forum by clicking HERE .The market had a bit of a 'hiccup' in early trading on Thursday. However, after declining nearly 2.5% in the first hour of trading, the NASDAQ clawed back most of those early losses to end Thursday just over .7% inBret Jensen has over 1 ...

Core Viewpoint - A class action lawsuit has been filed against Vistagen Therapeutics, Inc. for allegedly providing misleading information regarding its Phase 3 PALISADE-3 trial of fasedienol, leading to significant investor losses [2][7]. Group 1: Lawsuit Details - The lawsuit is on behalf of all individuals and entities who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, inclusive [2]. - Investors have until March 16, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [2]. Group 2: Allegations - The complaint alleges that Vistagen made overwhelmingly positive statements while concealing material adverse facts about the Phase 3 PALISADE-3 trial [7]. - On December 17, 2025, Vistagen announced that the PALISADE-3 study did not show a statistically significant improvement on its primary endpoint, leading to a dramatic stock price decline from $4.36 to $0.86, a drop of over 80% [7]. Group 3: Next Steps for Investors - Investors who suffered losses or have information regarding the case are encouraged to contact Bragar Eagel & Squire for further assistance [4].

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that it is investigating potential securities claims on behalf of shareholders of Corcept Therapeutics Incorporated (NASDAQ: CORT) resulting from allegations that Corcept may have issued materially misleading business information to the investing public. So What: If you purchased Corcept securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fe. ...

Financial Data and Key Metrics Changes - The preliminary results of the voting indicated that the compensation of the named executive officer was approved on an advisory basis [12] - The appointment of MaloneBailey, LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026, was ratified [13] Business Line Data and Key Metrics Changes - No specific financial data or key metrics related to business lines were provided in the meeting [2][3] Market Data and Key Metrics Changes - No specific market data or key metrics were discussed during the meeting [2][3] Company Strategy and Development Direction - The company is focused on good corporate practices, as evidenced by the advisory vote on executive compensation and the ratification of the auditor's appointment [10][11] Management Comments on Operating Environment and Future Outlook - Management noted that forward-looking statements regarding future events or financial performance involve risks and uncertainties, and actual results could differ materially from predictions [14] Other Important Information - The meeting was held virtually, and all necessary procedures for voting and quorum were followed [5][6] - The company emphasized the importance of investor sentiment regarding executive compensation [9][10] Q&A Session Summary - No questions were submitted by stockholders during the Q&A session, leading to the conclusion of the meeting [15]

Financial Data and Key Metrics Changes - The preliminary results of the voting indicated that the compensation of the named executive officer has been approved on an advisory basis [12] - The appointment of MaloneBailey, LLP as the company's independent registered public accounting firm for the fiscal year ending December 31, 2026, has been ratified [13] Business Line Data and Key Metrics Changes - No specific data or metrics related to individual business lines were discussed during the meeting Market Data and Key Metrics Changes - No specific market data or metrics were provided in the meeting Company Strategy and Development Direction and Industry Competition - The company is focused on good corporate practices, as evidenced by the advisory vote on executive compensation and the ratification of the independent auditor [11] Management's Comments on Operating Environment and Future Outlook - Management noted that forward-looking statements regarding future events or financial performance involve risks and uncertainties, and actual results could differ materially from predictions [14] Other Important Information - The meeting was held virtually, and all necessary procedures for voting and quorum were followed [5][6] - The company emphasized the importance of stockholder participation and the advisory nature of certain proposals [9][10] Q&A Session Summary - No questions were submitted by stockholders during the Q&A session, leading to the conclusion of the meeting without any inquiries [15]

McCourt said the EYLEA HD and EYLEA franchise delivered combined U.S. net sales of $1.1 billion in the fourth quarter, while noting EYLEA 2 mg U.S. net sales declined 15% sequentially to $577 million. She also cited new real-world data suggesting patients switching to EYLEA HD extended treatment duration by nearly four weeks on average.EYLEA HD: U.S. net product sales were $506 million in the fourth quarter, up 66%, and $1.6 billion for 2025, up 36%. Management attributed momentum to demand growth and label ...

Dow Jones Leader Amgen Leads These Biotechs Heading Into O4 Earnings | Investor's Business DailyBREAKING: [Trump Names Warsh New Fed Chairman] --- Biotech stocks continue to outperform in the current stock market rally, as Dow Jones index component and industry giant Amgen (AMGN), alone with Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Argenx (ARGX) trade in or near buy zones. Fourth-quarter earnings season is kicking into full swing, which will spur stock mar ...

Key Takeaways VKTX to report Q4 results with no revenues expected and a consensus loss of 89 cents per share.VKTX completed VANQUISH-1 enrollment for VK2735, VANQUISH-2 to complete enrollment later in 2026.Further updates on obesity, NASH, and X-ALD programs are expected during the Q4 earnings call.We expect investors to focus on Viking Therapeutics’ (VKTX) progress with the development of its lead candidate, VK2735, a dual agonist of the glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic ...

Immunocore Holdings plc (NASDAQ:IMCR) is one of the Best Small Cap Stocks Ready to Explode in 2026. On January 21, Patrick Trucchio from H.C. Wainwright reiterated a Buy rating on the stock with a $100 price target. Earlier, on January 6, UBS also initiated Immunocore Holdings plc (NASDAQ:IMCR) with a Buy rating and a $55 price target. ​Analysts at UBS see significant potential upside for the stock because it is currently trading close to the value of its approved drug Kimmtrak. The firm noted that this ...